Nephron Pharmaceuticals responds to the coronavirus crisis
March 17, 2020
Nephron Pharmaceuticals, headquartered in West Columbia, is a global leader in the manufacturing of generic respiratory medications As such, they are at the forefront of manufacturing drugs that are being used to treat symptoms of the coronavirus (COVID-19). Nephron’s production capacity is of utmost importance in delivering critical product to market.
In response to the crisis, Nephron is
1) ramping up production and hiring. They currently have 8 filling lines producing 18 million units across multiple product lines.
2) awaiting FDA approval to ramp up production of 5 or 6 additional products to help in the treatment of COVID19. Expedited approval by the FDA is critical to meeting the potential demand for products.
3) also aiding in the fight against the virus through the production of hand sanitizers
